Immunovia’s vision is to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
Listen to Immunovia’s conference call related to the planned changes announced on July 11, 2023.
Immunovia AB published the company’s Full Year Report 2023 on Wednesday, February 21, 2024, at 8:30 am CET.